Answers are grounded in this paper and cite their sources.
Reducing postprandial blood glucose (PBG) constitutes a core objective in the clinical management of diabetes mellitus. Urtica cannabina L., a traditional medicinal and edible homologous plant, is widely distributed in China; however, research on its pharmacological activity and chemical composition remains relatively scarce. In the present study, the PBG-lowering potential of U. cannabina L. was confirmed both in vitro and in vivo, and its chemical constituents were preliminarily identified by UPLC-triple-TOF-MS/MS for the first time. Notably, acarbose (8 mg/kg), a clinically approved first-line α-glucosidase inhibitor, and UCE20 (20% ethanol extract of U. cannabina L.) at 10 mg/kg both significantly reduced PBG levels. Furthermore, UPLC-triple-TOF MS/MS analysis combined with correlation analysis has preliminarily indicated that hydroxycinnamoyl quinates and flavonoid C-glycosides may serve as the primary bioactive components responsible for the PBG-lowering effect. These findings suggested U. cannabina L. holds potential as a medicinal ingredient or health food to assist in the regulation of PBG levels.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: